Diego Gabathuler becomes the new CEO of Geistlich

December 01, 2023

Geistlich Pharma AG has appointed Diego Gabathuler as its new CEO, effective December 1, 2023. He succeeds Ralf Halbach, who departed the company in August 2023.  

Diego Gabathuler is a 49-year-old Swiss National who brings a broad range of experience from various management positions as well as extensive knowledge in business development and strategic marketing.

Most recently, he was CEO of the dental company Ivoclar. He has expertise in the MedTech sector, excellent leadership qualities, and a proven strategic acumen. His professional career also includes management positions at international digital-tech companies such as Logitech, Activision, and Electronic Arts.  

Andreas Geistlich, Chairman of the Board of Directors, who held the CEO position on an interim basis: “The Geistlich strategic plan includes further investment in new products, solutions, and technologies in order to apply regenerative medicine in helping even more people around the world. We are convinced that Diego Gabathuler’s expertise will support us significantly in this mission.”  

Geistlich wishes Diego a successful start, and we look forward to working with him to further advance the future of regenerative medicine. 

Geistlich appoints Diego Gabathuler as new CEO. As a proven leader, he brings many years of experience in the MedTech industry and will continue to drive the company’s expansion strategy in regenerative medicine.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

This begins with our world-class bone substitute Geistlich Bio-Oss® and Geistlich vallomix™, the first allograft/xenograft bone substitute. Resorbable collagen membrane Geistlich Bio-Gide® extends its reach with Geistlich Bio-Gide® Compressed for an alternative handling experience.

Our collagen matrix Geistlich Mucograft® is ideal for soft-tissue regeneration, and our volume-stable collagen matrix breakthrough Geistlich Fibro-Gide® provides an alternative to connective tissue grafts. Finally, our GEM 21S®, a growth-factor-enhanced matrix, is engineered to stimulate wound healing and bone regeneration.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:


Social Media




  1. iData Research Inc., US Dental Bone Graft Substitutes and other Biomaterials Market, 2022.
  2. iData Inc., European Dental Bone Graft Substitutes and other Biomaterials Market, 2015.